We are live on ! Find out more
CLDI icon

Calidi Biotherapeutics

21 hedge funds and large institutions have $354K invested in Calidi Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.01% less ownership

Funds ownership: 0.05%0.03% (-0.01%)

38% less funds holding

Funds holding: 3421 (-13)

46% less capital invested

Capital invested by funds: $656K → $354K (-$302K)

67% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 18

Holders
21
Holders Change
-13
Holders Change %
-38.24%
% of All Funds
0.28%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
6
Increased
6
Reduced
2
Closed
18
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
RWI
26
Red Wave Investments
Pennsylvania
-$18.6K -421 Closed
Citadel Advisors
27
Citadel Advisors
Florida
-$16.4K -371 Closed
State Street
28
State Street
Massachusetts
-$14.1K -319 Closed
Northern Trust
29
Northern Trust
Illinois
-$11.2K -254 Closed
DWM
30
Drive Wealth Management
Utah
-$10.3K -234 Closed
HF
31
HRT Financial
New York
-$10K -227 Closed
Raymond James Financial
32
Raymond James Financial
Florida
-$7.15K -162 Closed
DIM
33
Delta Investment Management
California
-$4.83K -109 Closed
Commonwealth Equity Services
34
Commonwealth Equity Services
Massachusetts
-$3K -70 Closed
Goldman Sachs
35
Goldman Sachs
New York
-$3.04K -69 Closed
VF
36
Virtu Financial
New York
-$2K -53 Closed
AWE
37
Avidian Wealth Enterprises
Texas
-$2.3K -52 Closed
TRCT
38
Tower Research Capital (TRC)
New York
-$2.06K -47 Closed
BlackRock
39
BlackRock
New York
-$60 -1 Closed

CLDI Hedge Fund Activity: Q3 2025 in Review

21 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q3 2025, worth a combined $354K — down 46% from $656K a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of CLDI and 6 opened new positions — a net loss of 12 holders — while 2 trimmed existing stakes and 6 added.

The largest buyer was HighTower Advisors, adding an estimated $319K. The largest seller was Armistice Capital, exiting entirely with an estimated $182K sold.

  • 21 institutional investors held Calidi Biotherapeutics (CLDI) as of Q3 2025, down from 34 in Q2 2025.
  • Funds reported $354K of Calidi Biotherapeutics stock for Q3 2025, down 46% quarter-over-quarter.
  • 6 funds opened new Calidi Biotherapeutics positions in Q3 2025 and 18 closed out, a net change of -12 holders.
  • The largest Calidi Biotherapeutics buyer in Q3 2025 was HighTower Advisors, an estimated $319K added.
  • The largest Calidi Biotherapeutics seller in Q3 2025 was Armistice Capital, an estimated $182K sold.

Based on aggregated 13F filings for Q3 2025.